Author:
Dawson Rodney,Diacon Andreas H,Everitt Daniel,van Niekerk Christo,Donald Peter R,Burger Divan A,Schall Robert,Spigelman Melvin,Conradie Almari,Eisenach Kathleen,Venter Amour,Ive Prudence,Page-Shipp Liesl,Variava Ebrahim,Reither Klaus,Ntinginya Nyanda E,Pym Alexander,von Groote-Bidlingmaier Florian,Mendel Carl M
Funder
Global Alliance for TB Drug Development
Global Alliance for TB Drug Development (TB Alliance)
Bill & Melinda Gates Foundation
US Agency for International Development
UK Department for International Development
Directorate General for International Cooperation of the Netherlands
Irish Aid
Australia Department of Foreign Affairs and Trade
Reference20 articles.
1. Tuberculosis;Zumla;N Engl J Med,2013
2. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis;Migliori;Eur Respir J,2013
3. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects;Zumla;Lancet Infect Dis,2014
4. Powerful bactericidal and sterilizing activity of a regimen containing PA824 moxifloxacin, and pyrazinamide in a murine model of tuberculosis;Nuermberger;Antimicrob Agents Chemother,2008
5. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial;Diacon;Lancet,2012